We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Issues Another No to Merck’s Keytruda for Advanced Bladder Cancer
NICE Issues Another No to Merck’s Keytruda for Advanced Bladder Cancer
The UK’s National Institute for Health and Care Excellence (NICE) has decided it will not fund Keytruda (pembrolizumab), Merck’s second-line advanced bladder cancer drug.